71432-55-8 Usage
Description
2-tert-Butyl-1,3-diisopropylisourea is an organic compound that serves as a crucial synthetic intermediate in the pharmaceutical industry. It is characterized by its ability to react with various compounds, making it a versatile building block for the synthesis of complex molecules.
Uses
Used in Pharmaceutical Synthesis:
2-tert-Butyl-1,3-diisopropylisourea is used as a synthetic intermediate for the production of 5-Oxo Atorvastatin tert-Butyl Ester (O847160), which is a Boc-protected derivative of Atorvastatin. Atorvastatin is a widely prescribed drug for the treatment of high cholesterol and related cardiovascular conditions. The use of this compound in the synthesis process allows for the efficient and effective production of the final drug product.
Additionally, 2-tert-Butyl-1,3-diisopropylisourea is used as a reagent in the total synthesis of Citrafungin A, an antifungal natural product. Citrafungin A is known for its potent antifungal activity against various fungal pathogens, making it a valuable compound in the development of new antifungal treatments. The use of 2-tert-Butyl-1,3-diisopropylisourea in this synthesis process contributes to the development of novel and effective antifungal therapies.
Physical Form
liquid
Check Digit Verification of cas no
The CAS Registry Mumber 71432-55-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,4,3 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 71432-55:
(7*7)+(6*1)+(5*4)+(4*3)+(3*2)+(2*5)+(1*5)=108
108 % 10 = 8
So 71432-55-8 is a valid CAS Registry Number.
71432-55-8Relevant articles and documents
RADIOACTIVELY LABELED SUBSTANCE
-
, (2012/03/26)
Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.